Chronic myelogenous leukemia (CML): An update

National Medical Journal of India

Volumn 19, Issue 5, 2006, Pages 255-263

  Kumar, Lalit ^a  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BCR ABL PROTEIN; BUSULFAN; CANCER VACCINE; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HOMOHARRINGTONINE; HYDROXYUREA; IMATINIB; NILOTINIB; PARACETAMOL; PEGINTERFERON; POTASSIUM BICARBONATE; RECOMBINANT ALPHA INTERFERON; ALPHA INTERFERON; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADVANCED CANCER; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BLAST CELL CRISIS; BLOOD EXAMINATION; BLOOD TOXICITY; BONE MARROW APLASIA; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CHILL; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONCENTRATION LOSS; COST EFFECTIVENESS ANALYSIS; CYTOGENETICS; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG INDICATION; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; ENZYME INHIBITION; FATIGUE; FEVER; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HIGH RISK PATIENT; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; LUNG FIBROSIS; LUNG TOXICITY; MEMORY DISORDER; META ANALYSIS; MOLECULAR BIOLOGY; MONOTHERAPY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL EDEMA; PHILADELPHIA 1 CHROMOSOME; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PLEURA EFFUSION; RASH; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SIDE EFFECT; SKIN TOXICITY; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION; ALLOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; RISK FACTOR; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; HUMANS; HYDROXYUREA; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PYRIMIDINES; RISK ASSESSMENT; RISK FACTORS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 33845621026     PISSN: 0970258X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. National Cancer Registry Programme. Two year report of the population based cancer registries 1999-2000. New Delhi:Indian Council of Medical Research; 2005.
3. Bhutani M, Vora A, Kumar L, Kochupillai V. Lympho-hemopoietic malignancies in India. Med Oncol 2002;19:141-50.
4. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-40.
5. Kumar L, Kumari M, Kumar S, Kochupillai V, Singh R. Clinical and laboratory features at diagnosis in 437 patients with chronic myelogenous leukemia: An experience of a tertiary care center. In: Kumar L (ed). Progress in haematologic oncology. New York:The Advanced Research Foundation, 2003:83-93.
6. Prabhu M, Kochupillai V, Sharma S, Ramachandran P, Sundaram KR, Bijlani L, et al. Prognostic assessment of various parameters in chronic myeloid leukemia. Cancer 1986;58:1357-60.
7. Kumar L, Sager TG, Maitreyan V, Majhi U, Shanta V. Chronic granulocytic leukaemia: A study of 160 cases. J Assoc Physicians India 1990;38:899-902.
8. Savage DG, Szydlo RM, Goldman JM. Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. Br J Haematol 1997;96:111-16.
9. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 1994;84:4064-77.
10. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-52.
11. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-302.
12. Kantarjian HM, Bueso-Ramos CE, Talpaz M, O'Brien S, Giles F, Faderl S, et al. Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy. Cancer 2005;104:777-30.
13. Nowell P, Hungerford D. A minute chromosome in human chronic granulocytic leukemia. Science 1960;132:1497.
14. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290-3.
15. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 1988;319:990-8.
16. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824-30.
17. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247:1079-82.
18. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343-56.
19. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28-37.
20. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-20.
21. Stephens DJ, Lawrence JS. The therapeutic effect of solution of potassium arsenite in chronic myelogenous leukemia. Ann Intern Med 1936;9:1488.
22. Medical Research Council's working party for therapeutic trials in leukaemia. Chronic granulocytic leukaemia: Comparison of radiotherapy and busulphan therapy. Report of the Medical Research Council's working party for therapeutic trials in leukaemia. BMJ 1968;1:201-8.
23. Sacie G, Clift RA, Blaise D, Devergie A, Ringden O, Martin PJ, et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: Long-term follow-up of 4 randomized studies. Blood 2001;98:3569-74.
24. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
25. Deininger MW, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003;21:1637-47.
26. Ozer H, George SL, Schiffer CA, Rao K, Rao PN, Wurster-Hill DH, et al. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival: Cancer and Leukemia Group B study 8583. Blood 1993;82:2975-84.
27. Alimena G, Morra E, Lazzarino M, Liberati AM, Montefusco E, Inverardi D, et al. Interferon alpha-2b as therapy for patients with Ph′-positive chronic myelogenous leukemia. Eur J Haematol (Suppl) 1990,52:25-8.
28. Kloke O, Niederle N, Qiu JY, Wandl U, Moritz T, Nagel-Hiemke M, et al. Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukaemia. Br J Haematol 1993;83:399-403.
29. Thaler J, Gastl G, Fluckinger T, Niederwieser D, Huber H, Seewann K et al. Treatment of chronic myelogenous leukemia with interferon alfa-2c: Response rate and toxicity in a phase II multicenter study. The Austrian Biological Response Modifier (BRM) Study Group. Semin Hematol 1993;30:17-19.
30. Mahon FX, Montastruc M, Faberes C, Reiffers J. Predicting complete cytogenetic response in chronic myelogenous leukemia patients treated with recombinant interferon alpha. Blood 1994;34:3592-4.
31. Schofield JR, Robinson WA, Murphy JR, Rovira DK. Low doses of interferon-alpha are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia. Ann Intern Med 1994;121:736-44.
32. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med 1995;122:254-61.
33. Kumar L, Gangadharan VP, Rao DR, Saikia T, Shah S, Malhotra H et al. Safety and efficacy of an indigenous recombinant interferon-alpha-2b in patients with chronic myelogenous leukaemia: Results of a multicentre trial from India. Natl Med J India 2005;18:66-70.
34. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994;330:820-5.
35. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-alpha for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 1995;345: 1392-7.
36. Ohnishi K, Ohno R, Tomonaga M, Kamada N, Onozawa K, Kuramoto A, et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995;86:906-16.
37. The Benelux CML Study Group. Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-alpha 2b for chronic myeloid leukemia. Blood. 1998;91:2713-21.
38. Hasford J, Baccarani M, Hehlmann R, Anseri H, Tura S, Zuffa E. Interferon-alpha and hydroxyurea in early chronic myeloid leukemia: A comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-alpha. Blood 1996;87:5384-91.
39. Chronic Myeloid Leukemia Trialists' Collaborative Group. Interferon alfa versus chemotherapy for chronic myeloid leukemia: A meta-analysis of seven randomized trials. J Natl Cancer Inst 1997;89:1616-20.
40. Kumar L, Gulati SC. Alpha-interferon in chronic myelogenous leukaemia. Lancet 1995,346:984-6.
41. Kluin-Nelemans HC, Buck G, le Cessie S, Richards S, Beverloo HB, Falkenburg JH, et al. Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: Prospective collaboration of 3 joint trials by the MRC and HOVON groups. Blood 2004;103:4408-15.
42. Deininger MWN. Chronic myeloid leukemia: Management of early stage disease. In: Berliner N, Lee SJ, Linenberger M, Bogelsang GB (eds). American Society of Hematology Education Program Book. Atlanta, Georgia:American Society of Hematology; 2005:174-82.
43. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997;337:223-9.
44. Baccarani M, Rosti G, de Vivo A, Bonifazi F, Russo D, Martinelli G, et al. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood 2002;99:1527-35.
45. Michallet M, Maloisel F, Delain M, Hellmann A, Rosas A, Silver RT, et al. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: A phase III study. Leukemia 2004;18:309-15.
46. Savage DG, Antman KH. Imatinib mesylate - A new oral targeted therapy. N Engl J Med 2002;346:683-93.
47. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
48. O'Brien SG, Guilhot F, Larson RA. Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
49. Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: Results from the IRIS Study. J Clin Oncol 2003;21:2138-46.
50. Arora B, Kumar L, Kumaru M, Sharma A, Wadhwa J, Kochupillai V. Therapy with imatinib mesylate for chronic myeloid leukemia. Indian J Med Paediatr Oncol 2005;26:5-18.
51. Deshmukh C, Saikia T, Bakshi A, Amare-Kadam P, Baisane C, Parikh P. Imatinib mesylate in chronic myeloid leukemia: A prospective, single arm, non-randomized study. J Assoc Physicians India 2005;53:291-5.
52. Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Rios MB, Shan J, et al. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: Comparison with historic data. Cancer 2003;98:2636-42.
53. Kantarjian H, Talpaz M, O'Brien S, Giles F, Faderl S, Verstovsek S, et al. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia - Comparison with historic experience. Cancer 2005;103: 2099-108.
54. Lahaye T, Riehm B, Berger U, Paschka P, Muller MC, Kreil S, et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: A 4.5-year follow-up. Cancer 2005;103:1659-69.
55. Velpandian T, Mathur R, Agarwal NK, Arora B, Kumar L, Gupta SK. Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci 2004;804:431-4.
56. Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004;103:2873-8.
57. Aoki E, Kantarijian HM, O'Brien S, Talpaz M, Giles F, Garcia-Manero G, et al. High dose imatinib mesylate treatment in patients (Pts) with untreated early chronic phase (CP) chronic myeloid leukemia (CML): 2.5 year follow up. Proc Am Soc Clin Oncol 2006;24:345a (Abstract 6535).
58. Gardembas M, Rousselot P, Tulliez M, Vigier M, Buzyn A, Rigal-Huguet F, et al. Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase. Blood 2003;102:4298-305.
59. Baccarani M, Martinelli G, Rosti G, Trabacchi E, Testoni N, Bassi S, et al. Imatinib and pegylated human recombinant interferon-alpha 2b in early chronic-phase chronic myeloid leukemia. Blood 2004;104:4245-51.
60. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-41.
61. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542-51.
62. Druker BJ. Circumventing resistance to kinase-inhibitor therapy. N Engl J Med 2006;354:2594-6.
63. Arora B, Kumar L, Sharma A, Wadhwa J, Kochupillai V. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate. Ann Oncol 2004;15:358-9.
64. Vora A, Bhutani M, Sharma A, Raina V. Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase. Ann Oncol 2002;13:1833-4.
65. Lokeshwar N, Kumar L, Kumari M. Severe bone marrow aplasia following imatinib mesylate in a patient with chronic myelogenous leukemia. Leuk Lymphoma 2005;46:781-4.
66. Goldman J, Gordon M. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: Does it really matter? Leuk Lymphoma 2006;47:1-7.
67. Shah NP. Loss of response to imatinib: Mechanisms and management. In: Berliner N, Lee SJ, Linenberger M, Bogelsang GB (eds). American Society of Hematology Education Program Book. Atlanta, Georgia:American Society of Hematology; 2005:183-7.
68. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423-32.
69. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-30.
70. Goldman JM, Melo JV. Chronic myeloid leukemia - Advances in biology and new approaches to treatment. N Engl J Med 2003;349:1451-64.
71. Talpaz M, Apperley JF, Kim DW, Silver RT, Bullorsky EO, Iyer M, et al. Dasatinib (D) in patients with accelerated phase chronic myeloid leukemia (AP-CML) who are resistant or intolerant to imatinib: Results of the CA180005 'START-A' study. Proc Am Soc Clin Oncol 2006;24:343a (Abstract 6526).
72. Coutre S, Martinelli G, Dombret H, Hochhaus A, Larson R, Saglio G, et al. Dasatanib (D) in patients (pts) with chronic myelogenous leukemia (CML) in lymphoid blast crisis (LB-CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are imatinib (IM)-resistant (IM-R) or intolerant (IM-I): The CA180015 'START-L' study. Proc Am Soc Clin Oncol 2006;24:6528.
73. Estrov Z, O'Brien S, Giles F, Garcia-Manero G, Borthakur G, Ravandi F, et al. Dasatinib (EMS 354825), a dual Src-abl inhibitor, is active in Philadelphia chromosome positive chronic myelogeneous leukemia (Ph+ve CML) following treatment with imatinib mesylate and AMN 107. Proc Am Soc Clin Oncol 2006;24: 344a (Abstract 6530).
74. Cortes JE, Kim DW, Rosti G, Rousselot P, Bleickrdt E, Zinc R, et al. Dasatinib (D) in patients (pts) with chronic myelogenous leukemia (CML) in myeloid blast crisis (MBC) who are imatinib-resistant (IM-R) or IM-intolerant (IM-I): Results of the CA180006 'START-B' study. Proc Am Soc Clin Oncol 2006;24:6529.
75. La Coutre PD, Ottmann O, Gatterman N, Larson R, Rafferty T, Alland L, et al. A phase II study of AMN107, a novel inhibitor of BCR-ABL, administered to imatinib-resistant or intolerant patients (pts) with chronic myelogenous leukemia (CML) in accelerated phase (AP). Proc Am Soc Clin Oncol 2006;24:6531.
76. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras H, Devergie A, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998;352:1087-92.
77. Passweg JR, Walker I, Sobocinski KA, Klein JP, Horowitz MM, Giralt SA. Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. Br J Haematol 2004;125:613-20.
78. Goldman JM, Rizzo JD, Jabocinski KA, et al. Long term outcome after allogeneic stem cell transplantation for CML (Abstract). Hematol J 2004;5:98 (Abstract 288).
79. Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: Transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006;91:513-21.
80. Clift RA, Anasetti C. Allografting for chronic myeloid leukaemia. Baillieres Clin, Haematol 1997;10:319-36.
81. Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998;338:962-8.
82. Schattenberg AV, Dolstra H. Cellular adoptive immunotherapy after allogeneic stem cell transplantation. Curr Opin Oncol 2005;17:617-21.
83. Dazzi F, Szydlo RM, Cross NC, Craddock C, Kaeda J, Kanfer H, et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000;96:2712-16.
84. Kumar L. Leukemia: Management of relapse after allogeneic bone marrow transplantation. Leukemia 2004;7:202-10.
85. Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange A, Brune M, et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: An analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005;106:2969-76.
86. Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, Tabilio A, et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: A multicentre observational trial. Lancet 2005;365:657-62.
87. Sharma P, Mohanty S, Kumar L. A vaccine for chronic myeloid leukaemia. Natl Med J India 2005;18:146-7.